{"id":53247,"date":"2023-01-24T18:02:59","date_gmt":"2023-01-24T17:02:59","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/maat-pharma-provides-corporate-update-and-highlights-key-expected-milestones-in-2023\/"},"modified":"2023-01-24T18:02:59","modified_gmt":"2023-01-24T17:02:59","slug":"maat-pharma-provides-corporate-update-and-highlights-key-expected-milestones-in-2023","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/maat-pharma-provides-corporate-update-and-highlights-key-expected-milestones-in-2023\/","title":{"rendered":"MaaT Pharma Provides Corporate Update and Highlights Key Expected Milestones in 2023"},"content":{"rendered":"
\n

LYON, France–(BUSINESS WIRE)–$MAAT<\/a>–Regulatory News:\n<\/p>\n

<\/a><\/p>\n

\nMaaT Pharma<\/a><\/b> (EURONEXT: MAAT \u2013 the \u201cCompany\u201d), a French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem TherapiesTM<\/sup> (MET) dedicated to improving survival outcomes for patients with cancer, <\/b>provides a corporate update highlighting the progress, adjustments to clinical programs and key development milestones expected in 2023.\n<\/p>\n

\n\u201cMaaT Pharma has delivered important clinical milestones during 2022 including the expansion of its development pipeline with the launch of two clinical trials for its lead drug candidate, MaaT013 in hemato-oncology (Phase 3) and in immuno-oncology (Phase 2a). The year 2022 also marks an important milestone for the global microbiome industry with the regulatory approvals of the first microbiome-based drugs by the FDA in the U.S. and by the TGA in Australia,\u201d <\/i>stated<\/b> Herv\u00e9 Affagard, CEO and co-founder of MaaT Pharma.<\/b> \u201cDespite difficult market conditions, we continue to advance our pioneering science and technology and we remain focused on delivering new therapeutic solutions to the benefit of patients with severe conditions as well as building value for our shareholders. 2023 will be a year with important inflection points and will require us to act decisively to reach our objectives. We thank our investors for their support throughout this year, and their confidence in our ability to achieve the next level of corporate development.\u201d<\/i>\n<\/p>\n

\nClinical development<\/b>\n<\/p>\n

\nHemato-oncology<\/b>\n<\/p>\n

\nMaaT013, a full-ecosystem, standardized, pooled-donor native Microbiome Ecosystem Therapy for acute, hospital use (enema administration)\n<\/p>\n

\nMaaT013 for the treatment of acute Graft-versus-Host Disease (aGvHD)<\/b>: MaaT013 has received an Orphan Drug Designation by both the U.S. Food and Drug Administration (FDA) and the European Medical Agency (EMA).\n<\/p>\n